Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Tel: 353-1-669-8559 or 800-462-3636
174 articles with Endo International plc
Endo International plc will announce its first-quarter 2019 financial results on May 9, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States
Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck's PROVENTIL® HFA Inhalation Aerosol, 120mcg.
Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes
Endo International plc announced the early tender results of the previously announced cash tender offers made by Endo Finance LLC, a wholly-owned subsidiary of Endo International plc, for the debt securities listed in the table below.
Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery
Leading Peer-Reviewed Dermatology Journal Features Phase 2 Data
Endo International plc announced that Par Pharmaceutical, Inc., its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount.
Endo International plc announced an upsizing of its previously announced cash tender offers and consent solicitations by Endo Finance LLC, a wholly-owned subsidiary of Endo International plc.
Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, intends to offer senior secured notes, subject to market and customary conditions
Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes
Endo International plc (NASDAQ: ENDP) today announced a series of debt refinancing transactions that are intended to help manage the debt maturity profile of it and certain of its subsidiaries (collectively, the "Company" or "Endo"). These refinancing transactions are expected to include:
Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Cowen & Company 39th Annual Healthcare Conference in Boston, Massachusetts on Monday, March 11, 2019 at 2:10 p.m. ET.
Endo International plc announced that the U.S. Food and Drug Administration has determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act.
Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting
Endo International plc (NASDAQ: ENDP) today announced that it will present new data showing collagenase clostridium histolyticum (CCH) significantly met the clinical endpoint of improved cellulite severity and appearance and was well tolerated in recent Phase 3 clinical trials.
Endo International plc reported fourth-quarter 2018 financial results
Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited
Endo International plc announced that its subsidiaries, Endo Ventures Limited, Par Pharmaceutical, Inc.
Endo Agrees Not To Oppose Additional Stay of FDA Litigation Following Restoration of Government Appropriations
Endo International plc ("Endo") (NASDAQ: ENDP) today announced that the U.S. Food and Drug Administration (the "FDA") has requested a further stay of Endo's ongoing litigation against the FDA through March 15, 2019.
Endo International plc will announce its fourth-quarter and full-year 2018 financial results on February 28, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.
Endo Announces Anticipated Further Stay of Compounding Litigation Due to Lapse of Government Appropriations
Endo International plc today announced that, due to the ongoing federal government shutdown, the U.S. Food and Drug Administration (the "FDA") has requested a further stay of Endo's ongoing litigation against the FDA for the duration of the shutdown.
J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 7, 2019 at 11:30 a.m. PST.
Endo International plc announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference in Boca Raton, Florida on Tuesday, December 4, 2018 at 9:30 a.m. ET.
Third-quarter 2018 revenues of $745 million compared to third-quarter 2017 revenues of $787 million
Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
Both RELEASE-1 and RELEASE-2 Studies Demonstrated Highly Statistically Significant Results (P=0.006 and P=0.002 respectively) on Efficacy Endpoints